Altuviiio: A Once-Weekly Treatment for Hemophilia A
FDA-approved in February 2023, Sanofi’s Altuviiio is a long-acting antihemophilic factor (recombinant) used to treat hemophilia A in children and adults. Learn about its mechanism of action, dosage, side effects, cost, and more.
